Comments*

 
  • Academy Events

  • Equivalence of Complex Drug Products: Scientific and Regulatory Challenges

    Wednesday, November 9, 2016 | 8:30 AM - 5:15 PM
    The New York Academy of Sciences

    Presented by the Non Biological Complex Drugs Working Group (NBCD WG), the Nanotechnology Characterization Laboratory (NCL) of the Frederick National Lab for Cancer Research, and the New York Academy of Sciences

    The rise of bio- and nano-technologies has accelerated the development of complex drug products, a class of products that include—but are not limited to—Non Biological Complex Drugs (NBCDs). NBCDs (e.g., glatiramoids, iron-carbohydrate complexes, polymeric micelles, complex ocular emulsions, and liposomes) consist of different (closely related and often nanoparticulate) structures that cannot be fully quantitated and characterized by physico-chemical analytical means. The complex nature of NBCDs means that minute variations in the manufacturing process can substantially change the composition of final products, and this poses a challenge for the development of regulatory guidelines. While guidance for developing generic versions of small molecule drugs is well-established, and progress has been made for biologic complex drugs, there is very little guidance for follow-on versions of NBCDs. This is further complicated by the difficulty of aligning strategies of international regulatory bodies due to their different legal frameworks. To advance research and build consensus, it is necessary to engage together key stakeholders from academia, regulatory bodies, industry, and drug manufacturing.

    To stimulate this discussion, the Non Biological Complex Drugs Working Group, the Nanotechnology Characterization Laboratory (NCL) of the Frederick National Lab for Cancer Research, and the New York Academy of Sciences, will present the conference Equivalence of Complex Drug Products: Scientific and Regulatory Challenges. This convening aims to identify the best approaches for complex drug development and regulation, to outline outstanding challenges in the assessment of complex drug equivalence and consequences for interchangeability of products, to address whether the regulatory approaches for biosimilars should be used as models for other complex drugs, and to clarify differences and commonalities in the behavior of biological and NBCD families. The end goal is to facilitate the translation of scientific findings into advancements in medicine and to ensure the safety and benefit of patients.

    Call for Abstracts

    Abstract submissions are invited for a poster session. For complete submission instructions, please send an email to ComplexDrugs16@nyas.org with the words "Abstract Information" in the subject line. There is no need to type a message; instructions will be forwarded automatically. Abstracts will be accepted on a rolling basis until all available poster presentation spaces are filled.

    Registration Pricing

      By 10/17/2016 After 10/17/2016 Onsite
    Member $90 $105 $120
    Member (Student / Postdoc / Resident / Fellow) $40 $50 $60
    Nonmember (Academia) $125 $150 $175
    Nonmember (Corporate) $220 $260 $295
    Nonmember (Non-profit) $125 $150 $175
    Nonmember (Student / Postdoc / Resident / Fellow) $70 $80 $90

    Registration includes a complimentary, one-year membership to the New York Academy of Sciences. Complimentary memberships are provided to non-members only and cannot be used to renew or extend existing or expiring memberships. A welcome email will be sent upon registration which will include your membership credentials.


    Presented by

    • Non Biological Complex Drugs Working Group (NBCD WG)
    • Nanotechnology Characterization Laboratory (NCL) of the Frederick National Lab for Cancer Research
    • The New York Academy of Sciences
    EmailPrint